X

Trial Profile

Combination trial of CEND-1 and immunotherapies in various solid tumor cancers patients

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 15 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cerepetide (Primary) ; Immunotherapies (Primary)
Indications Solid tumours
Focus Proof of concept; Therapeutic Use
Sponsors Cend Therapeutics; Lisata Therapeutics

Most Recent Events

09 May 2023 According to a Lisata Therapeutics media release, the company expects to start this combination study with corresponding standards-of-care before the end of the second quarter of 2023.
10 Nov 2022 According to a Lisata Therapeutics media release, the company expects to start this combination study with corresponding standards-of-care in the first half of 2023.
18 Feb 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com